Prevention Of Venous Thromboembolism In Undergoing Surgery — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of venous thromboembolism in undergoing surgery. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
6
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevention Of Venous Thromboembolism In Undergoing Surgery

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of venous thromboembolism in undergoing surgery. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xarelto
rivaroxaban
 Johnson & Johnson 6 62 — 2034-02-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto other 62 2034-08-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17
9539218 Xarelto method of use 62 2034-02-17

Related